Anti-Staphylococcal Activity of the Auranofin Analogue Bearing Acetylcysteine in Place of the Thiosugar: An Experimental and Theoretical Investigation

• Published in: Molecules (Basel, Switzerland) Vol. 27; no. 8; p. 2578
• Main Authors: Chiaverini, Lorenzo, Pratesi, Alessandro, Cirri, Damiano, Nardinocchi, Arianna, Tolbatov, Iogann, Marrone, Alessandro, Di Luca, Mariagrazia, Marzo, Tiziano, La Mendola, Diego
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 16.04.2022; MDPI
• Subjects: Acetylcysteine; Acetylcysteine - pharmacology; Acetylcysteine - therapeutic use; Anti-Bacterial Agents - pharmacology; Anti-Bacterial Agents - therapeutic use; Antibacterial activity; antibacterial agents; antibiotic resistance; Antibiotics; Antimicrobial agents; Arthritis; auranofin; Auranofin - chemistry; Auranofin - pharmacology; Bacterial diseases; Bacterial infections; Binding; Biological activity; Drug resistance; Gold; Gram-positive bacteria; Human serum albumin; Humans; Ligands; Mode of action; Nosocomial infections; Oral administration; Peptides; Pharmacology; Proteins; Rheumatoid arthritis; S. aureus; S. epidermidis; Serum albumin; Staphylococcal Infections - drug therapy; Staphylococcus aureus; Staphylococcus infections; S. epidermidis; gold; acetylcysteine; auranofin; S. aureus; antibiotic resistance; antibacterial agents; ESI-MS; computational chemistry; metal-based drugs

Auranofin (AF, hereafter) is an orally administered chrysotherapeutic agent approved for the treatment of rheumatoid arthritis that is being repurposed for various indications including bacterial infections. Its likely mode of action involves the impairment of the TrxR system through the binding of...